Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Weaves Worldwide Web Of Partnerships In Quest For Innovative Drugs, CEO Says

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Facing the imminent expiration of American patents on some of its leading drugs, Takeda is building a matrix of partnerships and licensing arrangements in the quest to strengthen its sales of innovative products, according to CEO Yasuchika Hasegawa

You may also be interested in...



Takeda Research Investment’s Graeme Martin On Corporate Venture Capital’s Role in Developing Next-Generation Biologics: An Interview With PharmAsia News(Part 2 of 2)

Attend any industry conference these days, and a general theme arises that venture capital is not as readily available as it once was. A dearth of venture funding, particularly for early-stage projects, could impact long-term future development of emerging biotechnologies.

Takeda Research Investment’s Graeme Martin On Corporate Venture Capital’s Role in Developing Next-Generation Biologics: An Interview With PharmAsia News(Part 2 of 2)

Attend any industry conference these days, and a general theme arises that venture capital is not as readily available as it once was. A dearth of venture funding, particularly for early-stage projects, could impact long-term future development of emerging biotechnologies.

Corporate Venture Capital’s Role In Developing Next-Generation Biologics: An Interview With Takeda Research Investment’s Graeme Martin (part 2 of 2)

With private-equity investments in early-stage financing gone, corporate venture needs to support these opportunities, “because if you don’t, the biotechnology industry is going to disappear. It’s just going to dry up,” Martin maintains.

Related Content

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel